Terug
45
Dagbereik
€ 68,03
€ 69,18
52-Weeksbereik
€ 67,56
€ 109,50
Volume
9.654.607
50D / 200D Gem.
€ 80,41
/
€ 95,75
Vorige Slotkoers
€ 69,54
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 35,0 | 0,3 |
| P/B | 4,2 | 2,9 |
| ROE % | 12,6 | 3,7 |
| Net Margin % | 14,4 | 3,8 |
| Rev Growth 5Y % | 14,0 | 10,0 |
| D/E | 0,5 | 0,2 |
Koersdoel Analisten
Hold
€ 108,35
+59.0%
Low: € 94,00
High: € 130,00
Forward K/W
20,1
Forward WPA
€ 3,47
WPA Groei (sch.)
+0,0%
Omzet Sch.
22 B
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 5,61
€ 5,52 – € 5,77
|
33 B | 2 |
| FY2029 |
€ 4,98
€ 4,91 – € 5,12
|
30 B | 2 |
| FY2028 |
€ 4,44
€ 4,01 – € 5,09
|
27 B | 4 |
Insider Trading Activity
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 |
Morano Susan E
Director
|
grant | 24 | — | — |
| Mar 2, 2026 |
Pegus Cheryl
Director
|
grant | 24 | — | — |
| Mar 1, 2026 |
Woodworth Emily
SVP, Global Controller and CAO
|
other | 2.048 | — | — |
| Nov 28, 2025 |
O'Sullivan Miriam
SVP, Chief HR Officer
|
other | 260 | — | — |
| Nov 14, 2025 |
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
|
other | 9.610 | — | — |
| Nov 12, 2025 |
Fitzgerald Joseph Michael
EVP & Group Pres, Cardiology
|
other | 690 | — | — |
| Aug 1, 2025 |
LUDWIG EDWARD J
Director
|
other | 500 | — | — |
| Jul 29, 2025 |
FUJIMORI YOSHIAKI
Director
|
sell | 2.901 | € 106,99 | € 310.378 |
| Jul 1, 2025 |
Monson Jonathan
EVP and CFO
|
grant | 30.523 | — | — |
| May 29, 2025 |
LUDWIG EDWARD J
Director
|
sell | 4.000 | € 104,59 | € 418.368 |
| May 21, 2025 |
Brown Vance R
SVP, GC and Corp. Secretary
|
sell | 4.826 | € 106,42 | € 513.583 |
| May 8, 2025 |
Habiger David C
Director
|
grant | 2.081 | — | — |
| May 8, 2025 |
WICHMANN DAVID S
Director
|
grant | 2.081 | — | — |
| May 8, 2025 |
Mega Jessica L
Director
|
grant | 2.081 | — | — |
| May 8, 2025 |
Zane Ellen M
Director
|
grant | 2.081 | — | — |
| May 8, 2025 |
LUDWIG EDWARD J
Director
|
grant | 2.081 | — | — |
| May 5, 2025 |
Sorenson John Bradley
EVP, Global Operations
|
sell | 4.572 | € 104,54 | € 477.957 |
| May 2, 2025 |
Sorenson John Bradley
EVP, Global Operations
|
other | 10.326 | — | — |
| May 2, 2025 |
Butcher Arthur C
EVP& Grp Pres, MedSurg & APAC
|
other | 5.221 | — | — |
| Apr 21, 2025 |
Brown Vance R
SVP, GC and Corp. Secretary
|
sell | 4.826 | € 95,09 | € 458.904 |
Belangrijkste Punten
Revenue grew 13,99% annually over 5 years — strong growth
Earnings grew 55,66% over the past year
ROE of 12,55% — decent returns on equity
Generating 3,66B in free cash flow
P/E of 35,04 — premium valuation
PEG of 0,88 suggests growth is underpriced
Groei
Revenue Growth (5Y)
13,99%
Revenue (1Y)19,87%
Earnings (1Y)55,66%
FCF Growth (3Y)46,56%
Kwaliteit
Return on Equity
12,55%
ROIC8,13%
Net Margin14,38%
Op. Margin19,78%
Veiligheid
Debt / Equity
0,51
Current Ratio1,62
Interest Coverage11,38
Waardering
P/E Ratio
35,04
P/B Ratio4,17
EV/EBITDA28,08
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 19,87% | Revenue Growth (3Y) | 18,73% |
| Earnings Growth (1Y) | 55,66% | Earnings Growth (3Y) | 34,60% |
| Revenue Growth (5Y) | 13,99% | Earnings Growth (5Y) | 29,07% |
| Profitability | |||
| Revenue (TTM) | 20,07B | Net Income (TTM) | 2,89B |
| ROE | 12,55% | ROA | 6,61% |
| Gross Margin | 69,01% | Operating Margin | 19,78% |
| Net Margin | 14,38% | Free Cash Flow (TTM) | 3,66B |
| ROIC | 8,13% | FCF Growth (3Y) | 46,56% |
| Safety | |||
| Debt / Equity | 0,51 | Current Ratio | 1,62 |
| Interest Coverage | 11,38 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 35,04 | P/B Ratio | 4,17 |
| P/S Ratio | 5,04 | PEG Ratio | 0,88 |
| EV/EBITDA | 28,08 | Dividend Yield | 0,00% |
| Market Cap | 101,13B | Enterprise Value | 111,50B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 20,07B | 16,75B | 14,24B | 12,68B | 11,89B |
| Net Income | 2,89B | 1,85B | 1,59B | 698,00M | 1,04B |
| EPS (Diluted) | 1,94 | 1,25 | 1,07 | 0,45 | 0,69 |
| Gross Profit | 13,85B | 10,27B | 8,83B | 7,71B | 7,46B |
| Operating Income | 3,97B | 2,64B | 2,18B | 1,82B | 1,92B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 43,67B | 39,40B | 35,14B | 32,47B | 32,23B |
| Total Liabilities | 19,20B | 17,39B | 15,61B | 14,90B | 15,61B |
| Shareholders' Equity | 24,23B | 21,77B | 19,28B | 17,57B | 16,62B |
| Total Debt | 12,42B | 11,15B | 9,49B | 9,28B | 9,45B |
| Cash & Equivalents | 2,05B | 414,00M | 865,00M | 928,00M | 1,93B |
| Current Assets | 8,79B | 6,92B | 6,51B | 5,76B | 6,32B |
| Current Liabilities | 5,44B | 6,40B | 4,93B | 3,80B | 4,27B |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#528 of 1052
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026